SYN101 / Synthis Therap - LARVOL DELTA

SYN101, a first in class, immune cell targeted TGF-beta inhibitor therapy, selectively blocks immune suppression and drives tumor clearance in vitro and in vivo (SITC 2022) - "Safer, more effective TGF-b therapies, like SYN101, will provide novel monotherapy options for cancer patients. Additionally, because TGF-b sets the overall threshold for T cell activation, SYN101 could improve the efficacy of a variety of therapies, including checkpoint inhibition, radiation and NK/CAR-T therapies."

IO biomarker • Preclinical • Breast Cancer • Colorectal Cancer • Gastrointestinal Cancer • Hematological Malignancies • Lymphoma • Melanoma • Oncology • Solid Tumor • CD4 • CD69 • CD8 • GZMB • IFNG • TGFB1 • TGFBR1